BioInsights - Access to vaccines: how can we leverage technology innovations to achieve greater vaccine equity?

Access to vaccines: how can we leverage technology innovations to achieve greater vaccine equity?

Vaccine Insights 2022; 1(4), 235–240

DOI: 10.18609/vac/2022.034

Published: 20 September 2022
Podcast
Fatema Kazi


Fatema Kazi is an Immunologist working at the WHO’s R&D Blueprint Team–part of the Health Emergencies and Preparedness Response. Previously, she has worked at the Elizabeth Glaser Pediatric AIDS Foundation, GAVI, UNOPS, The Stop TB Partnership, and the Global TB Programme (WHO) focusing on research and development in innovative therapeutics, vaccines, and diagnostics. She has a PhD in Cellular Immunology and Infectious Diseases from the London School of Hygiene and Tropical Medicine, and pursued her postdoctoral career as a Senior Immunologist Research Fellow at Leiden University Medical Centre and the University of Oxford, as well as training as a molecular biologist for the Ministry of Defense, UK. In response to the pandemic, Fatema has been leading projects at WHO related to tracking, monitoring, and assessing the development of the COVID-19 vaccine candidates worldwide, conducting epidemiological reviews of vaccine effectiveness against variants of concern. She is now evaluating vaccines for Monkeypox, Lassa Fever and Sudan ebolavirus in response to the current outbreaks.

Fatema Kazi works for the WHO, where she helps to assess the public health value of vaccine products and technologies in routine, campaign, and outbreak settings. We caught up with her to discuss how innovations in vaccine technology can help get vaccines to the people who need them.